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OBJECTIVE: The aim of this study was to investigate the presence of growth hormone receptor in plexiform neurofibromas of
neurofibromatosis type 1 patients.
INTRODUCTION: The development of multiple neurofibromas is one of the major features of neurofibromatosis type 1. Since
neurofibromas commonly grow during periods of hormonal change, especially during puberty and pregnancy, it has been suggested
that hormones may influence neurofibromatosis type 1 neurofibromas. A recent study showed that the majority of localized
neurofibromas from neurofibromatosis type 1 patients have growth hormone receptor.
METHODS: Growth hormone receptor expression was investigated in 5 plexiform neurofibromas using immunohistochemistry.
RESULTS: Four of the 5 plexiform neurofibromas were immunopositive for growth hormone receptor.
CONCLUSION: This study suggests that growth hormone may influence the development of plexiform neurofibromas in patients
with neurofibromatosis type 1.
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INTRODUCTION
Neurofibromatosis type 1 (NF1), also known as von
Recklinghausen´s disease, is an autosomal dominant dis-
order caused by mutations in the NF1 gene, which is lo-
cated on chromosome 17q11.2.1,2 NF1 is the most common
form of neurofibromatosis (NF) and is one of the most fre-
quently occurring human genetic diseases, with a preva-
lence of 1 in 3,000 births.3
Neurofibromas, café-au-lait spots, freckling in the in-
guinal and axillary regions and Lisch nodules develop in
most affected patients.1,4 The defining feature of NF1 is the
development of multiple neurofibromas.2,5 In clinical terms,
these tumors can be classified into two major groups: lo-
calized (or discrete) and plexiform.2,5 Localized neurofibro-
mas are the most common type of neurofibroma in NF1,
and present as a focal mass with well-defined margins. 2,5
Most of these tumors begin to appear in later childhood,
especially in early puberty. 2, 5 Their number varies widely
between patients and tends to increase over time. 2,5 In spite
of their presence in large numbers, localized neurofibro-
mas rarely, if ever become malignant. 5
Plexiform neurofibromas are almost always associated
with NF1 and occur in only about 30% of all patients. They
are the main source of morbidity in NF1 individuals, due
to their tendency to grow to large sizes and their capacity
to cause significant deformity. 2,5,6 Malignant transforma-
tion into malignant peripheral nerve sheath tumors
(MPNST) occurs in 4% of these tumors and is the main
cause of mortality in adult patients with NF1. 2,5,6 Plexi-
form neurofibromas are thought to be congenital in origin,40
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and those that involve the skin usually become visible
within the first two years of life. 5, 6, 7
Based on the observation that neurofibromas commonly
increase in size and number during periods of hormonal
change, especially during puberty and pregnancy, it has
been suggested that hormones may influence neurofibroma
growth in NF1 patients.8, 9, 10, 11, 12, 13
Since high plasma levels of growth hormone (GH) oc-
cur during adolescence, it is possible that this hormone may
influence the growth of neurofibromas in NF1 individuals.
Our previous study showed that most patients with NF1
have localized neurofibromas that express growth hormone
receptor (GHR), suggesting that GH may play a role in the
development of these neoplasms.12 The aim of this study
was to investigate the presence of GHR in plexiform neu-
rofibromas of NF1 patients.
METHODS
This study was approved by the ethics committee of
Fluminense Federal University, Brazil.
Patients
Five plexiform neurofibromas from NF1 patients were
retrieved from the files of the pathological anatomy serv-
ice of Antônio Pedro University Hospital of Fluminense
Federal University (Table 1).
All patients included in this study were diagnosed with
NF1 according to the diagnostic criteria established at the
1987 National Institutes of Health (NIH) Consensus De-
velopment Conference on Neurofibromatosis14 (Table 2).
Immunohistochemistry
Serial 5 µm sections were cut from paraffin wax blocks
and collected on silane-coated slides. After dewaxing,
GHR presence was detected immunohistochemically us-
ing the EnVision kitTM (code K1392; Dako, Capenteria,
California, USA). Briefly, antigen retrieval was performed
using a microwave oven and citrate buffer in a pressure
cooker. Endogenous peroxidase activity was eliminated by
incubation for 10, 15 and 20 minutes in 6% H2O2 in dis-
tilled water at room temperature. Non-specific protein
binding was blocked by incubation with a 1/100 dilution
of normal goat serum in antibody diluent with background
reducing component (code S3022; Dako) for 30 minutes
at 37 oC. Sections were incubated: (1) overnight at 4 oC
with a 1/100 dilution of the primary monoclonal antibody
against GHR (263; code MCA 1555; Serotec, Raleigh,
North Carolina, USA); or (2) for one hour at room tem-
perature with EnVisionTM. Visualization of bound antibody
was performed by incubation for 5 minutes in
diaminobenzidine. Between each step, sections were
washed three times for 10 minutes in Tris buffered saline.
All incubations were carried out in humidified chambers
to prevent evaporation. Sections were counterstained in
Mayer’s haematoxylin and coverslipped with Entellan
(code 107961; Merck, Frankfurt, Bradenburg, Germany).
Negative controls were performed by omitting the primary
monoclonal antibody, and normal fetus bone marrow was
used as a positive control.
RESULTS
Sections of normal epidermis and dermal appendages
showed immunoreactivity for GHR and served as positive
internal controls. All layers of the epidermis showed
immunopositivity for GHR, except for the keratin layer.
Hair follicles and sebaceous glands were also GHR
immunopositive . The excretory ducts of sweat glands
showed immunoreactivity only in the basal cells, and no
immunoreaction was seen in the cells of the secretory por-
tion of sweat glands. Vascular endothelial cells and skel-
etal muscle cells also possessed GHR immunoreactivity.
The control sections were negative for GHR.
Table 1 - Clinical data from patients
Case Age (yr) Sex Race Localization
1 19 F W Genital (skin)
2 9 F W Front (skin)
3 43 F B Nose (skin)
4 14 F B Abdomen (skin)
5 21 F B Supra orbit region (skin)
W= white; B= black
Table 2 - Diagnostic criteria for Neurofibromatosis type 1
(NF1) established by the National Institutes of Health
Consensus Development Conference (1988)15
Individual is affected with NF1 if two or more of the following conditions
are met:
￿ Six or more café au lait macules over 5 mm in greatest diameter in pre-
pubertal individuals and over 15 mm in greatest diameter in post-pubertal
individuals.
￿ Two or more neurofibromas of any type, or one plexiform neurofibroma.
￿ Freckling in the axillary or inguinal regions.
￿ Optic glioma.
￿ Two or more Lisch nodules (iris hamartomas).
￿ A distinctive osseous lesion such as sphenoid dysplasia or thinning of
long bone cortex, with or without pseudoarthrosis.
￿ A first-degree relative with NF1 by the above criteria.41
CLINICS 2008;63(1):39-42 Identification of growth hormone receptor in plexiform neurofibromas
Cunha KSG et al.
Immunohistochemical analyses in neurofibromas
Of the five plexiform neurofibromas studied, four were
immunopositive for GHR. In two plexiform neurofibromas,
staining was seen only in the nucleus and cytoplasm. One
plexiform neurofibroma had immunoreactivity associated
with the nucleus and cellular membrane. In the other
immunopositive plexiform neurofibromas, the immunore-
activity could be detected in the nuclei, cytoplasm and cel-
lular membrane. Staining was granular in all neurofibro-
mas. In two of the four immunopositive neurofibromas, the
pattern of staining was heterogeneous, whereas in the re-
maining two, the staining had a homogeneous distribution.
Table 3 summarizes the results of the immunohisto-
chemical analysis of plexiform neurofibromas. Figure 1
shows typical GHR immunohistochemistry results.
DISCUSSION
Neurofibromin, the protein transcribed by the NF1 gene,
contains a region that has high similarity to Ras-specific
GTPase-activating proteins (GAPs).15 Both neurofibromin
and GAP reduce cell proliferation by accelerating the in-
activation of the Ras protein, which has a pivotal role in
mitogenic intracellular signaling pathways.16 Therefore,
mutations in the NF1 gene cause an increased risk of de-
veloping both benign (mainly neurofibromas) and malig-
nant neoplasms (mainly MPNST), supporting the classifi-
cation of NF1 as a tumor predisposition syndrome.2,5
GH acts on cells by binding to GHR and can activate a
variety of signaling pathways to exert its effects upon mi-
togenesis, differentiation and metabolism.17 Interestingly,
the Ras pathway, which is altered in NF1 patients, is one
of the pathways used by GH. 18,19
In the present study, it was observed that four of five
plexiform neurofibromas from NF1 patients expressed
GHR. Therefore, high levels of GH during puberty could
cause the growth of these neoplasms.
Lincoln et al.30 verified using immunohistochemistry,
that the ratio of immunopositive cells for GHR was higher
in neoplasias than in normal tissues. An increased incidence
of benign and malignant neoplasias has been detected in
individuals with acromegaly.20,21,23,24,31 A role for GH in
neoplastic dissemination has also been suggested, since it
was observed that patients with prostate cancer who de-
veloped metastases had higher serum concentrations of GH
than patients without metastases.25 An increased incidence
of leukemia has also been reported in individuals treated
with recombinant GH.22,32
NF1 patients may have short stature, and some NF1
children with short stature of unknown cause have been
treated with recombinant GH.33 Since many studies have
suggested that GH is a potent inducer of cell growth in
many neoplasias, the safety of GH in NF1 patients has been
questioned.20-32
The presence of GHR in plexiform neurofibromas does
not necessarily prove that this hormone plays a role in the
development of plexiform neurofibromas in NF1 patients,
but their presence at least suggests the capacity of these
lesions to respond to GH. Therefore, recombinant GH
should be used with caution when treating short stature NF1
children, especially those who have plexiform neurofi-
broma. It is important to emphasize that plexiform neurofi-
broma is the most common precursor of MPNST, which
has a very poor prognosis, and previous studies have sug-
gested that GH may influence the development of other
malignant neoplasms.2,5,6,21,22,25,26,27,28,29,31,32
Table 3 - Results of immunohistochemical analyses for GHR
Case GHR Localization of immunoreaction Pattern of immunoreaction Distribution of immunoreaction
1 + C; N granular homogeneous
2 + C; N; CM granular heterogeneous
3-
4 + C; CM granular heterogeneous
5 + C; N granular homogeneous
C= cytoplasm; CM= cellular membrane; N= nucleus
Figure 1 - Plexiform neurofibroma immunopositive for GHR (case number
5); 40x, immunohistochemistry.42
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CONCLUSIONS
Our results show that most plexiform neurofibromas
expressed GHR. Therefore, it is possible that GH may in-
fluence the development of these tumors. Although the con-
cept that GH can stimulate the growth of neurofibromas
in NF1 patients is still only a theory, the potential role of
GH in the development of these lesions cannot be ignored.
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